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Background: Rivaroxaban was the first new oral anticoagulant approved for treat-
ment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxa-
ban is noninferior to conventional anticoagulation for VTE in efficacy and safety. 
Increased fatigue after the initiation of rivaroxaban has been observed in clinical 
practice, but data on this potential side effect are lacking.
Objective: The study aimed to evaluate development of fatigue in patients treated 
for VTE, comparing rivaroxaban to other anticoagulants.
Methods: Patients were prospectively recruited after a diagnosis of VTE. The Fatigue 
Questionnaire was used to determine the level of fatigue at baseline, at 3 weeks of 
treatment, and either at 1 month after the discontinuation of treatment if the treat-
ment was discontinued after 3 months or at 6 months if treatment was continued 
beyond this time. Data was analyzed by a linear mixed model.
Results: A total of 126 patients were included. Mean age was 59 years; 77 (61%) 
were males. Fifty-seven patients (45%) were diagnosed with deep vein thrombosis, 
48 (38%) with pulmonary embolism, and 21 (17%) with both. Predicted changes in 
fatigue scores from baseline to the last measurement were −0.007 and −2.49 for the 
rivaroxaban and the other-anticoagulants groups, respectively, neither of which were 
statistically significant. No difference was detected between rivaroxaban and the 
other-anticoagulants group at any time point, including subgroup analysis comparing 
over and under 6 months of treatment duration.
Conclusion: In this small study, our results suggest no increase in the level of fatigue 
after the initiation of treatment with rivaroxaban for VTE.
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Essentials
• Increased fatigue has been observed in clinical practice after initiation of rivaroxaban for venous thromboembolism (VTE).
• Fatigue was assessed with the Chalder Fatigue Score in consecutive patients diagnosed with VTE.
• No significant change in fatigue was detected over time in patients treated with rivaroxaban.
• No difference in fatigue was detected between the rivaroxaban and the other-anticoagulants group.
1  | INTRODUCTION
Venous thromboembolism (VTE) comprises deep venous throm-
bosis (DVT) and pulmonary embolism (PE) and is treated with 
anticoagulation for a duration of time ranging from 3 months to in-
definitely, depending on the presence or absence of provoking fac-
tors, risk of recurrence, and bleeding.1 Until recently, warfarin was 
the only oral anticoagulant available.2 In the past decade, however, 
4 new direct oral anticoagulants have been introduced in clinical 
practice. In phase 3 studies, these agents were found equally ef-
fective and safe with regard to risk of recurrence and bleeding.3‒7 
Rivaroxaban, a direct oral factor Xa inhibitor, was the first drug to 
be approved for the treatment of VTE, followed by apixaban, dabi-
gatran, and edoxaban. In addition to their efficacy and safety pro-
file, these agents also demonstrate rapid and stable anticoagulation 
and reduced need for monitoring. This may in large part explain 
why the use of these agents has rapidly increased and, in many 
countries, to a great extent replaced warfarin for the treatment of 
VTE, with rivaroxaban and apixaban now being the 2 most widely 
used agents.8
Based on clinical observations in the follow-up period as 
well as personal communication with other treatment providers, 
a number of patients treated with rivaroxaban reported severe 
fatigue symptoms. To date, however, no studies have investi-
gated this possible side effect in patients with VTE treated with 
rivaroxaban.
Thus, the current study aimed to prospectively evaluate the 
course of fatigue in consecutive patients treated with anticoagula-
tion for VTE, comparing rivaroxaban to other anticoagulants.
2  | MATERIALS AND METHODS
This trial was a substudy to the Long-Term Outcomes of Venous 
Thromboembolism study (the LOVE study, NCT02268630). The 
LOVE study is an observational single-center trial conducted at 
Østfold Hospital Trust aiming to prospectively determine the 
prevalence of recurrence, bleeding, postthrombotic syndrome 
and chronic thromboembolic pulmonary hypertension at 2 and 
5 years after VTE, as well as changes in health-related quality of life. 
Consecutive patients ≥ 18 years of age with objectively verified VTE 
were included if written informed consent was obtained. Patients 
were excluded if their life expectancy was <6 months. A total of 356 
patients were included in the LOVE study between June 2014 and 
December 2017.
Patients were included in the fatigue substudy from 2016 after 
a protocol amendment in response to clinical observations of severe 
fatigue in some patients following the initiation of rivaroxaban. We 
included all patients, regardless of whether they were treated with 
rivaroxaban or other anticoagulants for comparative purposes using 
the same inclusion criteria as the main study cohort. Fatigue was 
measured using the Fatigue Questionnaire, which was originally de-
veloped by Chalder et al.9 The Fatigue Questionnaire consists of 11 
questions divided into 2 dimensions: physical fatigue (7 items) and 
mental fatigue (4 items). Four response options are used (0-4), and 
higher scores indicate higher levels of fatigue. Combining the scores 
of physical and mental fatigue produces a score for total fatigue, 
with a maximum score of 33. The questionnaire has been translated 
into Norwegian and psychometrically tested for validity, reliability, 
sensitivity, and responsiveness in the Norwegian general population, 
as well as certain disease cohorts, such as inflammatory bowel dis-
ease and non-Hodgkin lymphoma.10,11
Fatigue scores were obtained at baseline, at 3 weeks of treat-
ment, and either at 1 month after the discontinuation of treatment 
if the treatment was discontinued after 3 months or at 6 months if 
treatment was continued beyond this time. In other words, the last 
time point included 2 rivaroxaban subgroups; 1 was not on anticoag-
ulation at the time of measurement, and 1 was still on anticoagula-
tion after 6 months. The questionnaires were sent to the patients by 
mail, to be completed by the patients and returned to the hospital.
The Fatigue Questionnaire was introduced after the protocol was 
amended in 2016 and was therefore completed by only a subset of 
patients. Inclusion criteria were identical to the main study cohort. No 
TA B L E  1   Baseline patient characteristics
Characteristics
Rivaroxaban 
> 6 months  
(n = 59)
Rivaroxaban  






Male 39 14 23
Female 20 12 15
Mean Age, y 59.6 53.1 62.9
Diagnosis, n
DVT 27 21 9
PE 23 6 18
DVT + PE 9 1 11
Cancer 0 0 5
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism.
aOne patient on rivaroxaban <6 months was lost to follow-up. 
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formal hypothesis was planned to be tested in this study; however, a 
sample size of 70 patients receiving rivaroxaban and completing the 
Fatigue Questionnaire at 3 time points was set a priori to see if we could 
capture any signal of increased fatigue after rivaroxaban initiation.
Multiple measurements on the same patients are obviously cor-
related. This was accounted for by analyzing the data on fatigue 
score by a linear mixed model, using time and type of treatment 
(rivaroxaban or other anticoagulants) as explanatory variables and 
individuals as random effects. An interaction term allowed for dif-
ferent trends over time for the 2 treatment groups. The model was 
reduced by likelihood ratio tests. The linear mixed model implicitly 
assumes normal data. The model was checked by quantile-quantile 
and residual plots and gave no cause for concern. The subgroup anal-
ysis for rivaroxaban treatment duration was also analyzed by a linear 
mixed-effects model using treatment over 6 month versus under 6 
month and time as independent variables.
3  | RESULTS AND DISCUSSION
Fatigue scores were obtained from 174 patients at baseline, 126 at 
2 time points (rivaroxaban group: n = 88) and 95 at 3 time-points (ri-
varoxaban group: n = 67). As the aim of the study was to analyze the 
development of fatigue over time, only patients with at least 2 sepa-
rate fatigue measurements were included in the statistical analysis, 
corresponding to a response rate of 72% and 55% at the second and 
third time points, respectively, and a total of 126 patients included 
in the analysis. Of these patients, 88 were treated with rivaroxaban, 
18 with apixaban, 11 with enoxaparin, 7 with warfarin, and 2 with 
dabigatran. Of the 11 patients receiving enoxaparin, 5 had a diagno-
sis of cancer at the initiation of anticoagulant therapy.
Of the patients who completed the Fatigue Questionnaire at the 
third time point, 17 completed the questionnaire 1 month after ces-
sation of treatment, that is, at 4 months; 49 were still being treated 
with rivaroxaban at 6 months; and 28 were treated with other anti-
coagulation, excluding 1 patient lost to follow-up.
Mean age was 59 years (standard deviation, 12.25), and 77 of the 
patients (61%) were male. Fifty-seven (45%) were diagnosed with 
DVT, 48 (38%) with PE, and 21 (17%) had both DVT and PE. Baseline 
patient characteristics are summarized in Table 1. Average fatigue 
scores are demonstrated in Table 2.
Our results suggest a constant level in mean fatigue score over 
time for patients treated with rivaroxaban (Figure 1), including when 
analyzed for subgroups of treatment duration >6 months versus 
<6 months. No significant difference was detected between the 
treatment groups at any of the 3 measuring points (Table 2), includ-
ing at the third measuring time point when comparing patients being 
treated with rivaroxaban at 6 months to patients assessed 1 month 
after treatment cessation (Table 3). Predicted changes in fatigue 
scores from baseline to the last measurement were −0.007 and 
−2.49 for the rivaroxaban and the other-anticoagulants groups, re-
spectively, which were not statistically significant (Table 3). Change 
for the rivaroxaban group can be read from Table 3 as the sum of the 
time2 and time2:riv effects. The non–rivaroxaban treatment group 
showed a trend toward lower levels of fatigue from the second to 
the third time point but without being significant (Figure 1).
Although our results found no increase in fatigue, individual pa-
tients reported an increase in the level of fatigue after the initia-
tion of rivaroxaban, but this was also observed in patients receiving 
other anticoagulants. We cannot conclude whether the observed 
increase in fatigue in some patients is attributable to the treatment 
or the underlying VTE. However, Kovacs et al12 also found no dif-
ference in fatigue score when comparing short-term warfarin use to 
placebo despite observations of fatigue in the clinical setting. This 
TA B L E  2   Mean scores (standard deviation) for total, physical, and mental fatigue at the 3 time points in the study population receiving 
rivaroxaban or other anticoagulants
Fatigue score 
(SD)
Rivaroxaban ≥ 6 months Rivaroxaban < 6 months Other anticoagulants
T0 n = 59 T1 n = 59 T2 n = 49 T0 n = 28 T1 n = 28 T2 n = 17 T0 n = 38 T1 n = 38 T2 n = 28
Mental 
fatigue
4.5 (1.4) 4.6 (1.5) 5.3 (1.8) 3.9 (1.2) 4.5 (2.1) 4.5 (1.1) 4.9 (1.5) 5.0 (1.7) 4.5 (1.0)
Physical 
fatigue
11.1 (3.5) 10.6 (3.1) 10.7 (3.9) 10.5 (4.4) 9.9 (3.7) 9.1 (2.6) 11.6 (4.5) 11.0 (3.9) 9.1 (3.0)
Total fatigue 15.6 (4.2) 15.3 (3.8) 16.0 (5.1) 14.5 (5.1) 14.5 (4.3) 13.7 (3.2) 16.4 (5.5) 16 (5.1) 13.6 (3.4)
Abbreviations: SD, standard deviation; T0, baseline; T1, 3 weeks; T2, 4-6 months.
F I G U R E  1   Predicted mean of fatigue score with 95% confidence 
interval by treatment groups
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may indicate that the underlying thrombosis, not the anticoagulation 
itself, is a factor in the fatigue development.
The Fatigue Questionnaire has not previously been validated in a 
Norwegian VTE population, which represents a limitation to the study. 
Other limitations include a small sample size and missing/incomplete 
measurements from ≥1 time points. The latter is a well-known short-
coming of longitudinal studies, but the linear mixed model does make 
optimal use of the data by using all measurements and not only the 
complete cases. The lack of adjustment for comorbid conditions rep-
resents another limitation to the group comparison analysis.
In conclusion, in this small study, our results suggest no increase 
in the level of fatigue after the initiation of treatment with rivarox-
aban for VTE. However, in individual patients, an increase in fatigue 
score was observed, confirming occasional observations of fatigue 
in the clinical setting. Although occasionally practiced, it remains 
unknown whether switching to another oral anticoagulant could re-
lieve these patients’ fatigue.
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TA B L E  3   Parameter estimates for mixed-effects regression 
model for fatigue score
Parameter Estimate SE df t value P value
(Intercept) 16.42 0.73 217 22.41 <.0001
Time1 –0.42 0.71 217 –0.59 .55
Time2 2.49 0.79 217 3.14 .002
riv –1.22 0.88 124 –1.39 .17
Time1:riv 0.17 0.85 217 0.20 .84
Time2:riv 2.49 0.95 217 2.63 .009
Note: Reference group: first measuring point (time 0) and other 
anticoagulants (riv = 0).
Abbreviations: df, degrees of freedom; SE, standard error.
